Key Dates

Related Announcements

None

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

To solicit input on aspects regarding the National Institutes of Health (NIH) RECOVER-TLC effort.

Background

Today, there are no approved therapies to treat Long COVID or its symptoms, leaving millions of patients suffering and waiting for answers. Trying to counter this public health crisis, the NIH announced the next phase of its Long COVID research program: Researching COVID to Enhance Recovery–Treating Long COVID (RECOVER-TLC) led by National Institute of Allergy and Infectious Disease (NIAID), in collaboration with National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS). The goal of this initiative is to work rapidly, collaboratively, and transparently to advance treatments for Long COVID. RECOVER-TLC will apply lessons learned from the ongoing program, RECOVER, launched in 2021.

As an important first step, NIAID and the Foundation for NIH (FNIH) co-organized a hybrid workshop to introduce RECOVER-TLC and engage with scientific, patient, and industry communities on the new initiative. Moving forward, RECOVER-TLC will be assessing new ideas, identifying potential therapeutics, and conducting innovative clinical trials using platform study designs. Central to this initiative, RECOVER-TLC aims to have ongoing engagement to inform on various aspects of clinical trial planning and implementation.

Information Requested

NIAID seeks information or responses to the following topics:

1. Potential therapeutics for Long COVID
2. Interest in being involved on working groups (patients, caregivers, scientists, physicians, etc.)
3. Biomarkers to be used in Long COVID clinical trials
4. General feedback on RECOVER-TLC

How to Submit a Response

Ideas for therapeutics and biologics can be submitted via the RECOVER-TLC Intervention Information Request Form at the following link: https://customervoice.microsoft.us/Pages/ResponsePage.aspx?id=eHW3FHOX1UKFByUcotwrBq_OSKrO6dFHtebrdjkH2O1UNUdCQ1MzN1pJMVZFTzNDOTM5T1laWk5ETC4u.

Interest in serving on RECOVER-TLC working groups can be submitted via the following form: https://forms.office.com/Pages/ResponsePage.aspx?id=eHW3FHOX1UKFByUcotwrBgBgoh3lgudJmNHbGhE2p7FUODFUWExQNTQ5U0s2WlUzUTIzWlAzQ01CWi4u.

Biomarkers for Long COVID can be submitted via the following form: https://forms.office.com/Pages/ResponsePage.aspx?id=eHW3FHOX1UKFByUcotwrBgBgoh3lgudJmNHbGhE2p7FUNldKQ0UyQUlVS1JCOEk0QTBSVU5QRjNaTi4u.

General feedback on the RECOVER-TLC initiative can be submitted via the following form: https://forms.office.com/Pages/ResponsePage.aspx?id=eHW3FHOX1UKFByUcotwrBgBgoh3lgudJmNHbGhE2p7FUMFlVNE8ySjlSMEZMVTgxT1dVNFlaQzdVMi4u.

Responses may be submitted up until 12:00 AM EST February 1, 2025.

THIS INFORMATION IS REQUESTED FOR INFORMATION GATHERING PURPOSES ONLY.

Please note that contractors and collaborators of NIAID will review submissions under this RFI. Please do not include proprietary information in response to this RFI. Some high-level information (e.g. names of interventions and types of interventions) may be made public for reporting purposes.

Inquiries

Please direct all inquiries to:

[email protected]